Frontier Pharma Rheumatoid Arthritis - Cytokine Mediators Frontier Pharma Rheumatoid Arthritis | Page 5

7.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40) 37
7.2 Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2 (TYK2) 38
7.3 Pipeline Programs Targeting IL-10 and IL-18 39
7.4 Pipeline Programs Targeting 72 kDa Type IV Collagenase (MMP2) 41
7.5 Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7) 42
7.6 Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ) 43
7.7 Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5)
44
7.8 Pipeline Programs Targeting C-X-C Motif Chemokine 10 (CXCL10) and C-X-C Motif Chemokine
13 (CXCL13) 46
8 Strategic Consolidations 48
8.1 Industry-Wide First-in-Class Deals 48
8.2 Licensing Deals 49
8.3 Co-development Deals 52
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 56
9 Appendix 59
9.1 References 59
9.2 Abbreviations 63
9.3 Research Methodology 64
9.4 Secondary Research 64
9.4.1 Market Analysis 64
9.4.2 Pipeline Analysis 65
9.4.3 First-in-Class Matrix Assessment 65
9.4.4 First-in-Class Target Profiles 65
Follow Us: